Axsome's Alzheimer's Agitation Launch Faces First Full-Quarter Test As Shares Slide Toward Lows

Axsome Therapeutics heads into its third-quarter report with an awkward disconnect. Last quarter, management described a business hitting its stride, with new prescriptions inflecting higher, a freshly launched Alzheimer's disease agitation indication off to a fast start, and a doubled sales force finally in place. Since then the stock has fallen almost 33%, trailing the S&P 500 by more than 31 percentage points. The report due before the open on November 2 needs to show whether the commercial acceleration is real enough to close that gap.

The Street is asking for a lot. Consensus calls for revenue of $249.3 million, up 45.8% from $171.0 million a year ago and roughly 14% above the $218.4 million reported last quarter. The expected loss of $0.65 per share would be a sharp improvement from the $0.94 loss a year earlier and the $0.99 loss last quarter. Axsome does not guide on its sales ramp, so there is no company range to measure the forecast against. That leaves the prior call's operating data as the best guide to whether these numbers are realistic.

Those data are encouraging but still early. Avelity, the company's main revenue driver, posted $180.3 million in net sales last quarter, up 18% sequentially. The more telling detail was that new-to-brand prescriptions grew 26% while total prescriptions grew 12%. In the prior quarter the two had moved roughly in step. A gap like that usually signals future volume, and management credited the completed expansion to about 600 representatives. The agitation launch added fuel, with new prescriptions among patients 65 and older up 126% in its first eight weeks. Unique prescribers climbed to about 69,000 and payer coverage reached roughly 89% of lives. This quarter is the first full one with both the bigger sales force and the new indication. Continued outperformance in new prescriptions, plus clearer evidence that free samples are converting into paid scripts, would validate the story. A drop back toward parity between new and total prescriptions would suggest the early surge came mostly from sampling.

Sembravo is the second swing factor. Demand looked strong, with prescriptions up 30% sequentially to about 23,500. Reported net sales, however, fell to just $2.3 million. A prior-period adjustment and heavier use of patient support programs pushed gross-to-net deductions into the high-80% range. Management expects those deductions to normalize. If net revenue starts to track the prescription growth, that worry fades. Another quarter of weak pricing would raise questions about the economics of the drug.

Costs and cash will matter too. SG&A jumped to $208.1 million on launch spending, but management said it should level off. Last quarter revenue grew twice as fast as operating expenses. Repeating that pattern is how the narrower loss forecast gets delivered, and it supports management's claim that its $320 million in cash can carry the company to breakeven. On the pipeline, investors will want confirmation that the smoking cessation trial started on schedule. They will also want reassurance that binge eating disorder results remain on track for the fourth quarter, and an update on how Axsome plans to position AXS-12 against the orexin-2 competitor that reached the narcolepsy market first.

Sentiment has warmed noticeably even as the stock has fallen, moving from deeply bearish before the last report to nearly neutral now. The shares sit at $145, just above their post-earnings low of $143.90 and far below the 200-day moving average near $200. That combination of a bruised stock and less hostile sentiment lowers the bar for a relief move, but it does not guarantee one. The central question is simple: does the jump in new prescriptions turn into accelerating Avelity revenue? If it does, the gap between the business and the stock price becomes hard to justify. If it does not, last quarter's confidence will look premature.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It was generated automatically, with the help of AI, from Earnings Whispers and company data, and checked by Earnings Whispers before publication.